Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Mouse (Murine) BCL9 Anticorps:
anti-Human BCL9 Anticorps:
anti-Rat (Rattus) BCL9 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Both XBcl9 and XPygo2 are required to induce supernumerary axis and dorsal gene activation in Xenopus embryos.
Transcriptional cofactors Bcl9, Bcl9l (Montrer BCL9L Anticorps) and Pygo1 (Montrer PYGO1 Anticorps)/2 act independently of beta-catenin (Montrer CTNNB1 Anticorps) to ensure proper enamel formation.
ARX positively regulates Wnt (Montrer WNT2 Anticorps)/ beta-catenin (Montrer CTNNB1 Anticorps) signaling and the C-terminal domain of ARX interacts with the armadillo (Montrer PKP1 Anticorps) repeats in beta-catenin (Montrer CTNNB1 Anticorps) to promote Wnt (Montrer WNT2 Anticorps)/beta-catenin (Montrer CTNNB1 Anticorps) signaling. In addition, we found BCL9 and P300 (Montrer NOTCH1 Anticorps) also interact with ARX to modulate Wnt (Montrer WNT2 Anticorps)/beta-catenin (Montrer CTNNB1 Anticorps) signaling.
Study demonstrates that the Golgi resident protein GM130 (Montrer GOLGA2 Anticorps) activates the spindle assembly factor TPX2 (Montrer DAZL Anticorps) to nucleate microtubules around the Golgi and further captures them to couple mitotic membranes to the spindle.
Pax6 (Montrer PAX6 Anticorps), the master regulator of eye development, directly activates Bcl9/9l transcription.
These results suggest a critical role of BCL9/9-2 in the Wnt (Montrer WNT2 Anticorps)-mediated regulation of adult, as opposed to embryonic, myogenic progenitors.
Specific regulation of BCL9 expression by HIF-1alpha (Montrer HIF1A Anticorps) may prove to be an underlying crosstalk between Wnt (Montrer WNT2 Anticorps)/beta-catenin (Montrer CTNNB1 Anticorps) signaling and hypoxia signaling pathways.
Results find that BCL9 is upregulated in osteosarcoma (OS) tissues and promotes OS proliferation, migration and invasion. BCL9 is a downstream target of miR (Montrer MLXIP Anticorps)-1301 in OS cells. In addition, BCL9 restoration could reversed the functional effects of miR (Montrer MLXIP Anticorps)-1301 overexpression on OS cell proliferation, migration and invasion. These results revealed the important role of BCL9 in OS tumor progression.
High BCL9 expression is associated with cisplatin-resistance in non-small cell lung cancer.
miR (Montrer MLXIP Anticorps)-1301 inhibits hepatocellular carcinoma cell migration, invasion, and angiogenesis by decreasing Wnt (Montrer WNT2 Anticorps)/beta-catenin (Montrer CTNNB1 Anticorps) signaling through targeting BCL9.
results from this study demonstrated that hypoxia induced BCL-9 expression in human CRC (Montrer CALR Anticorps) cells mainly through HIF-1alpha (Montrer HIF1A Anticorps), which could be an important underlying mechanism for increased BCL-9 expression in CRC (Montrer CALR Anticorps).
SOX7 (Montrer SOX7 Anticorps) inhibits oncogenic beta-catenin (Montrer CTNNB1 Anticorps)-mediated transcription by disrupting the beta-catenin (Montrer CTNNB1 Anticorps)/BCL9 interaction.
The authors used CRISPR/Cas9 genome engineering of Drosophila legless (lgs) and human BCL9 and B9L (Montrer BCL9L Anticorps) to show that the C-terminus downstream of their adaptor elements is crucial for Wnt (Montrer WNT2 Anticorps) responses.
MEF2D (Montrer MEF2D Anticorps)-BCL9-positive patients had B-cell precursor immunophenotype and were characterized as being older in age, being resistant to chemotherapy, having very early relapse, and having leukemic blasts that mimic morphologically mature B-cell leukemia with markedly high expression of HDAC9 (Montrer HDAC9 Anticorps).
it was demonstrated that miR218 modulated a novel molecular target and the present study provided novel insights into potential mechanisms of RCC (Montrer XRCC1 Anticorps) oncogenesis.
findings indicate that BCL9 most likely does not harbor a common genetic variant that can increase the risk for schizophrenia in the Japanese population
BCL9 is associated with B-cell acute lymphoblastic leukemia. It may be a target of translocation in B-cell malignancies with abnormalities of 1q21. Its function is unknown. The overexpression of BCL9 may be of pathogenic significance in B-cell malignancies.
B-cell CLL/lymphoma 9
, B-cell lymphoma 9
, B-cell CLL/lymphoma 9 protein-like
, b-cell CLL/lymphoma 9 protein-like
, B-cell CLL/lymphoma 9 protein
, B-cell lymphoma 9 protein
, nuclear co-factor of beta-catenin signalling
, protein legless homolog